abstract: OBJECTIVE: The objective of the study was to conduct an analysis of pooled data from @entity7 @entity4 clinical trials to determine which @entity4 symptom and function domains drive @entity0 perception of improvement. DESIGN: Data from three double-blind, placebo-controlled trials of @entity7 in @entity4 @entity0 were pooled for this analysis. Changes in independent variables, including the Medical Outcomes Study 36-item Short-Form Health Survey, Medical Outcomes Study-Sleep Scale, sleep quality score from the daily sleep diary, @entity3 score from the daily @entity3 diary, @entity4 Impact Questionnaire, and Multidimensional Assessment of Fatigue were analyzed as predictors of outcome on the dependent variable, @entity0 Global Impression of Change (PGIC). Correlation analysis assessed relationships between the independent variables and PGIC. Cluster analysis identified @entity6 among variables, and a shrinkage and selection method and stepwise logistic regression determined rank order of variables. RESULTS: Improvement in PGIC at endpoint showed highest correlation with @entity3 improvement, fatigue, sleep, and work and physical function (0.4 < r < 0.6). Cluster analysis identified three main clusters of symptoms at endpoint: mood ( @entity2 and @entity5 ), @entity3 and sleep, and function and fatigue. @entity3 was ranked as the most important outcome explaining variability in PGIC, followed by @entity1 . CONCLUSIONS: @entity3 , fatigue, and sleep associate most strongly with improvement in PGIC. Physical- and work-related function also correlated with @entity0 ' overall assessment of improvement. These domains and their respective outcome measures can be used to improve assessment of @entity0 ' response to treatment.

title: Correlations between @entity4 symptom and function domains and @entity0 global impression of change: a pooled analysis of three randomized, placebo-controlled trials of XXXX .

answer: @entity7


abstract: OBJECTIVE: The objective of the study was to conduct an analysis of pooled data from @entity7 @entity4 clinical trials to determine which @entity4 symptom and function domains drive @entity0 perception of improvement. DESIGN: Data from three double-blind, placebo-controlled trials of @entity7 in @entity4 @entity0 were pooled for this analysis. Changes in independent variables, including the Medical Outcomes Study 36-item Short-Form Health Survey, Medical Outcomes Study-Sleep Scale, sleep quality score from the daily sleep diary, @entity3 score from the daily @entity3 diary, @entity4 Impact Questionnaire, and Multidimensional Assessment of Fatigue were analyzed as predictors of outcome on the dependent variable, @entity0 Global Impression of Change (PGIC). Correlation analysis assessed relationships between the independent variables and PGIC. Cluster analysis identified @entity6 among variables, and a shrinkage and selection method and stepwise logistic regression determined rank order of variables. RESULTS: Improvement in PGIC at endpoint showed highest correlation with @entity3 improvement, fatigue, sleep, and work and physical function (0.4 < r < 0.6). Cluster analysis identified three main clusters of symptoms at endpoint: mood ( @entity2 and @entity5 ), @entity3 and sleep, and function and fatigue. @entity3 was ranked as the most important outcome explaining variability in PGIC, followed by @entity1 . CONCLUSIONS: @entity3 , fatigue, and sleep associate most strongly with improvement in PGIC. Physical- and work-related function also correlated with @entity0 ' overall assessment of improvement. These domains and their respective outcome measures can be used to improve assessment of @entity0 ' response to treatment.

title: Correlations between XXXX symptom and function domains and @entity0 global impression of change: a pooled analysis of three randomized, placebo-controlled trials of @entity7 .

answer: @entity4


abstract: OBJECTIVE: The objective of the study was to conduct an analysis of pooled data from @entity7 @entity4 clinical trials to determine which @entity4 symptom and function domains drive @entity0 perception of improvement. DESIGN: Data from three double-blind, placebo-controlled trials of @entity7 in @entity4 @entity0 were pooled for this analysis. Changes in independent variables, including the Medical Outcomes Study 36-item Short-Form Health Survey, Medical Outcomes Study-Sleep Scale, sleep quality score from the daily sleep diary, @entity3 score from the daily @entity3 diary, @entity4 Impact Questionnaire, and Multidimensional Assessment of Fatigue were analyzed as predictors of outcome on the dependent variable, @entity0 Global Impression of Change (PGIC). Correlation analysis assessed relationships between the independent variables and PGIC. Cluster analysis identified @entity6 among variables, and a shrinkage and selection method and stepwise logistic regression determined rank order of variables. RESULTS: Improvement in PGIC at endpoint showed highest correlation with @entity3 improvement, fatigue, sleep, and work and physical function (0.4 < r < 0.6). Cluster analysis identified three main clusters of symptoms at endpoint: mood ( @entity2 and @entity5 ), @entity3 and sleep, and function and fatigue. @entity3 was ranked as the most important outcome explaining variability in PGIC, followed by @entity1 . CONCLUSIONS: @entity3 , fatigue, and sleep associate most strongly with improvement in PGIC. Physical- and work-related function also correlated with @entity0 ' overall assessment of improvement. These domains and their respective outcome measures can be used to improve assessment of @entity0 ' response to treatment.

title: Correlations between @entity4 symptom and function domains and XXXX global impression of change: a pooled analysis of three randomized, placebo-controlled trials of @entity7 .

answer: @entity0


abstract: During a 7-year period, 116 pancreas transplants were performed in 98 @entity1 @entity0 (49 with and 49 without previous kidney transplants) at the University of Minnesota. The posttransplant clinical course of 26 recipients (22%) was complicated by an @entity5 (8 with and 18 without previous kidney transplants). Infections occurred in 19/57 cases (33%) in which exocrine secretions were managed by enteric drainage, in 5/15 cases (33%) managed by free drainage into the peritoneal cavity, in 1/39 cases (3%) in which the duct was injected with a synthetic polymer, and in 1/2 cases (50%) in which a pancreaticocystostomy was performed. The organisms @entity4 , enterococci, bacteroides, and several anaerobes were cultured from the @entity0 with enteric drainage, while staphylococci were associated with the open duct drainage. @entity3 with Candida were found with all techniques. Surgical and percutaneous drainage was performed in all @entity0 . In 14 @entity0 , functioning and, in four @entity0 , nonfunctioning grafts were removed. In five @entity0 , the @entity2 resolved while the grafts were functioning, and these @entity0 are currently alive and well. Seven of the 26 @entity0 with @entity2 died (27% mortality rate), five after graft removal and two with the graft still in place (1 with and 1 without function), five in the open-duct, and one each in the enteric and urinary drainage categories. In the 90 cases without @entity5 , only six @entity0 died (4 cardiovascular, 1 anaphylaxis, 1 @entity6 ), for a mortality rate of 7%.

title: XXXX in pancreas transplant recipients.

answer: @entity5


abstract: AIMS: The aim of the study was assessment of the heterogeneity of stage IIIA @entity6 ( @entity6 ) and the late results of surgical treatment. METHODS: The study group consisted of 83 consecutive @entity0 discharged between 1988 and 1992 undergoing radical operative treatment for stage IIIA @entity6 . @entity5 was diagnosed in 54 (65.1%) @entity0 , @entity4 in 23 (27.7%), @entity3 in 2 (2.4%) and mixed (i.e. adenoid-squamous type) in 4 (4.8%). In respect of pTNM staging, 19 (22.9%) @entity0 had T3N1M0, 35 (42.2%) had T2N2M0 and 29 (34.9%) had T3N2M0. RESULTS: Overall, 13.3% of @entity0 with stage IIIA @entity6 survived 5 years following the operation and 8.7% survived 10 years. Analysis of follow-up study indicated that this group was heterogenic. In T3N1M0 group 26.3% survived 5 years following the operation, in T2N2M0 group 14.3%, in T3N2M0 group 3.5% (P = 0.015). Of 23 @entity0 with N2 disease and no @entity1 in hilar lymph nodes ('skip' @entity1 ), 26.1% survived 5 years, whereas none of 41 @entity0 with @entity1 spreading by continuity survived (P = 0.0015). If mediastinal lymph node @entity1 were diagnosed in one level, 25% @entity0 survived 5 years, but if two or more levels were affected, 2.3% only (P = 0.0214): 85.7% of @entity0 with well-differentiated (G1) @entity2 survived 5 years and 62.0% 10 years, whereas among those with moderately @entity2 , 11.8% and 8.8%, respectively. No @entity0 survived 5 years after resection of poorly differentiated (G3) @entity2 (P < 0.001). CONCLUSIONS: (1) @entity0 operated for stage IIIA @entity6 are a heterogeneous group, which makes it difficult to predict late results. (2) @entity0 operated for stage IIIA @entity6 have a better prognosis if @entity1 are discovered in level one mediastinal lymph nodes, particularly in the superior part of mediastinum, or if 'skip' @entity1 (pulmonary hilus unaffected) are discovered, as compared to those with N2 disease. (3) Poor histologic differentiation of the @entity2 is a bad prognostic factor.

title: Heterogeneity of stage IIIA XXXX ( @entity6 ) and evaluation of late results of surgical treatment.

answer: @entity6


abstract: AIMS: The aim of the study was assessment of the heterogeneity of stage IIIA @entity6 ( @entity6 ) and the late results of surgical treatment. METHODS: The study group consisted of 83 consecutive @entity0 discharged between 1988 and 1992 undergoing radical operative treatment for stage IIIA @entity6 . @entity5 was diagnosed in 54 (65.1%) @entity0 , @entity4 in 23 (27.7%), @entity3 in 2 (2.4%) and mixed (i.e. adenoid-squamous type) in 4 (4.8%). In respect of pTNM staging, 19 (22.9%) @entity0 had T3N1M0, 35 (42.2%) had T2N2M0 and 29 (34.9%) had T3N2M0. RESULTS: Overall, 13.3% of @entity0 with stage IIIA @entity6 survived 5 years following the operation and 8.7% survived 10 years. Analysis of follow-up study indicated that this group was heterogenic. In T3N1M0 group 26.3% survived 5 years following the operation, in T2N2M0 group 14.3%, in T3N2M0 group 3.5% (P = 0.015). Of 23 @entity0 with N2 disease and no @entity1 in hilar lymph nodes ('skip' @entity1 ), 26.1% survived 5 years, whereas none of 41 @entity0 with @entity1 spreading by continuity survived (P = 0.0015). If mediastinal lymph node @entity1 were diagnosed in one level, 25% @entity0 survived 5 years, but if two or more levels were affected, 2.3% only (P = 0.0214): 85.7% of @entity0 with well-differentiated (G1) @entity2 survived 5 years and 62.0% 10 years, whereas among those with moderately @entity2 , 11.8% and 8.8%, respectively. No @entity0 survived 5 years after resection of poorly differentiated (G3) @entity2 (P < 0.001). CONCLUSIONS: (1) @entity0 operated for stage IIIA @entity6 are a heterogeneous group, which makes it difficult to predict late results. (2) @entity0 operated for stage IIIA @entity6 have a better prognosis if @entity1 are discovered in level one mediastinal lymph nodes, particularly in the superior part of mediastinum, or if 'skip' @entity1 (pulmonary hilus unaffected) are discovered, as compared to those with N2 disease. (3) Poor histologic differentiation of the @entity2 is a bad prognostic factor.

title: Heterogeneity of stage IIIA @entity6 ( XXXX ) and evaluation of late results of surgical treatment.

answer: @entity6


abstract: @entity4 in situ (DCIS) represents a spectrum of heterogenous disease that accounts for approximately one fifth of all screen-detected @entity0 and is considered as a precursor of invasive @entity0 if left untreated (35-50% risk). DCIS can be treated by total mastectomy with or without immediate breast reconstruction, local excision (LE) plus adjuvant radiotherapy (RT) or LE alone. Total mastectomy is associated with low rates of local recurrence (1.4%) and @entity0 -specific mortality (0.59%). Three recent randomized controlled trials (RCTs) have demonstrated that adjuvant RT after LE of localized DCIS significantly reduces the incidence of local recurrence. However these trials did not identify any subgroups of @entity1 where RT could be safely omitted. Retrospective studies suggest that RT can be safely omitted after adequate LE (margin width > or =1 cm) of small (< 15 mm), non-high grade DCIS not associated with @entity2 . Further RCTs are required to validate these retrospective findings, with an emphasis on standardized and meticulous tissue processing and pathological evaluation. The role of adjuvant @entity3 in the management of DCIS continues to evolve. Formal axillary dissection is not appropriate for DCIS, however, the potential role of the sentinel node biopsy (SNB) in selected high risk cases requires further evaluation. The International Breast Cancer Intervention Study (IBIS-II) trial aims to evaluate the potential role of third generation aromatase inhibitors in postmenopausal @entity1 with hormone-sensitive DCIS.Future research will focus on the relevance of gene expression profiling, proteomics, Laser therapy and mammary ductoscopy to the management of DCIS.

title: Towards optimal management of XXXX in situ of the breast.

answer: @entity4


abstract: The @entity2 oncogene has been implicated in the processes of normal cell proliferation and differentiation. Elevated levels of @entity2 mRNA and its gene product (p62c-myc), have been detected in a variety of solid @entity1 and cultured cel lines. Its precise role in normal cell function and in neoplastic transformation and progression has yet to be elucidated. We have used a monoclonal antibody, raised by peptide immunisation, to determine the distribution by immunoperoxidase staining of the @entity2 oncogene product in archival specimens of @entity5 . Samples from 42 @entity0 with @entity3 , 24 with benign @entity4 and 15 normal colon biopsies were examined. Normal colon revealed maximum staining in the mid-zone of the crypts, corresponding to the zone of differentiation and maturation. The staining was predominantly cytoplasmic. @entity7 revealed the most intense pattern of staining in areas of @entity6 change. @entity1 showed a wide range of staining. Well differentiated @entity1 contained more cytoplasmic p62c-myc than poorly differentiated @entity1 . These findings suggest that the @entity2 oncogene product may play an important role in the evolution of @entity3 .

title: Detection of the @entity2 oncogene product in XXXX .

answer: @entity5


abstract: The @entity2 oncogene has been implicated in the processes of normal cell proliferation and differentiation. Elevated levels of @entity2 mRNA and its gene product (p62c-myc), have been detected in a variety of solid @entity1 and cultured cel lines. Its precise role in normal cell function and in neoplastic transformation and progression has yet to be elucidated. We have used a monoclonal antibody, raised by peptide immunisation, to determine the distribution by immunoperoxidase staining of the @entity2 oncogene product in archival specimens of @entity5 . Samples from 42 @entity0 with @entity3 , 24 with benign @entity4 and 15 normal colon biopsies were examined. Normal colon revealed maximum staining in the mid-zone of the crypts, corresponding to the zone of differentiation and maturation. The staining was predominantly cytoplasmic. @entity7 revealed the most intense pattern of staining in areas of @entity6 change. @entity1 showed a wide range of staining. Well differentiated @entity1 contained more cytoplasmic p62c-myc than poorly differentiated @entity1 . These findings suggest that the @entity2 oncogene product may play an important role in the evolution of @entity3 .

title: Detection of the XXXX oncogene product in @entity5 .

answer: @entity2


abstract: BACKGROUND: To evaluate therapeutic outcome of @entity1 treated with chemotherapy alone or combined with radiation therapy with different doses. METHODS: A retrospective analysis was performed in 128 @entity1 @entity0 who were treated with three different ways of treatment, from February 1988 to March 1998 in @entity1 Hospital. All @entity0 were pathologically proved. Forty-two @entity0 received chemotherapy alone (C), 48 @entity0 were treated by interdigitating chemoradiotherapy (IDG) and other 38 @entity0 received concurrent chemoradiotherapy (CON). For thoracic radiation, 20 @entity0 received a dose of  <=45 Gy, 23 >= 60 Gy, and 43 > 45 Gy but < 60 Gy . RESULTS: The 3-year survival rates were 23.7%, 20.8% and 4.8% in the CON, the IDG and the C groups respectively. There was a significant difference between the CON and the C groups ( P < 0.05), as well as between the IDG and the C groups ( P < 0.05). There was no remarkable difference between the CON and the IDG groups ( P > 0.05). Loco-regional recurrence rate was significantly higher in  <=45 Gy group (55.0%) than that in >= 60 Gy group (8.7%)( P < 0.01). CONCLUSIONS: The chemotherapy combined radiotherapy may improve the survival of @entity0 with @entity1 . Dose of thoracic radiation might be related to the loco-regional recurrence.

title: [Long-term results of chemotherapy alone or combined with radiation therapy for XXXX ].

answer: @entity1


abstract: The anatomic location of the adenoid implies that this organ is the first site of contact with inhaled antigens. Depending on the expression of different isoforms of the @entity4 molecules, T cells can be divided into naive (CD45RA(+)) and memory (CD45R0(+)) cells, the latter representing T cells that have already been exposed to antigens. The purpose of this study was to analyse the lymphoid cells' subsets in adenoids and relate the findings to the age. The analysed material was adenoid tissue removed on the grounds of @entity3 from 22 @entity0 . The @entity0 were divided into two groups: up to 5 and above 5 years of age. The analyses of the lymphocytes subpopulations in the adenoid were performed in an EPICX XL (Coulter) flow cytometry. The results are expressed as the percentage of positively labeled cells ( @entity1 (+), @entity2 (+), @entity1 (+)/CDB(+), @entity1 (+)CD45RA(+), @entity2 (+)CD45RA(+), @entity1 (+)CD45R0(+), @entity2 (+)CD45R0(+)). The percentage of @entity1 (+)/CD45R0(+) in @entity0 up to 5 years of age was significantly lower than in older @entity0 . We found the positive regression between age and the percentage of @entity1 (+) cells was CD45R0(+) (r=0.64). There were no statistically significant differences between study subgroups for the other parameters. The positive regression for @entity1 (+)/CD45R0(+) cells and age may result from increased stimulation by bacterial, viral and other antigens. Our results indicate that the adenoid have an important role in the development of an immunological memory among younger @entity0 .

title: Naive and memory T cells in hypertrophied adenoids in XXXX according to age.

answer: @entity0


abstract: During 11 acute open-chest experiments with @entity0 , intramyocardial pressure was measured in the anterior wall of the left ventricle with a miniature pressure transducer mounted on a 1.6 mm diameter needle. Pressures were measured at the subendocardium (+/- 10 mm), midwall (+/- 7.5 mm), and subepicardium (+/- 5 mm). Simultaneous recordings of left ventricular pressure and two measures of intramyocardial pressure were made during control, acute @entity1 , and after administration of @entity3 . Maximal amplitude of the subendocardial pressure was higher and the maximal amplitude of the subepicardial pressure was lower than maximal left ventricular pressure for all interventions (p less than 0.001 and p less than 0.01). During @entity1 left ventricular pressure increased more than intramyocardial pressure (left ventricular pressure 34%, subendocardial pressure 6%, midwall pressure 14%, and subepicardial pressure 14%). After the administration of @entity3 intramyocardial pressure decreased more than left ventricular pressure (left ventricular pressure 16%, subendocardial pressure 26%, midwall pressure 13%, subepicardial pressure 32%). Positive and negative first derivatives of subendocardial pressure were higher than those of left ventricular pressure during control and after @entity3 (between p less than 0.01 and p less than 0.001). Positive and negative first derivatives of subepicardial pressure were lower than those of left ventricular pressure during all interventions (p less than 0.001). The timing of the C-point (onset of mechanical contraction) and the positive first derivative of all tracings was synchronous within 8 msec in all interventions. The 0-point (crosspoint of the tangent to the diastolic plateau and the tangent to the relaxation slope; early diastole) of intramyocardial pressure came later than the 0-point of left ventricular pressure, indicating longer relaxation times in the @entity2 (subendocardial pressure: control, p less than 0.001, volume, p less than 0.05, @entity3 , no significance; midwall pressure: between p less than 0.05 and p less than 0.001; subepicardial pressure: between p less than 0.01 and p less than 0.001).

title: Intramyocardial pressure in the XXXX heart. An experimental study.

answer: @entity0


abstract: AIM: Surgery remains the main treatment of @entity3 . Poor long-term survival mandates the study of other techniques. An original treatment scheme with preoperative radiotherapy and @entity5 as a radiosensitizer is reported here. METHODS: Between 1982 and 1988, MRRC RAMS carried out a prospective clinical trial of preoperative radiotherapy (20 Gy/5 days) in combination with @entity5 (given orally, 3 times, 5 gms per metre(2)). Of 91 @entity0 who received preoperative radiotherapy, 67 @entity0 were operated on with curative intent and were eligible for further analysis. RESULTS: Acute gastro-intestinal @entity2 was significant but manageable without surgery delay in most cases. There were 4 postoperative deaths. Overall 5-year, 10-year survival and median survival were 46%, 36% and 46 months. Serosal and nodal involvement were the most significant adverse prognostic factors. Tumours confined to the gastric wall, node negative cases, middle and distal location, differentiated @entity1 , female sex and age more than 50 years were associated with relatively good long-term results: overall 5-year survival was 50% or better, overall 10-year survival was 40% or better. CONCLUSION: The combined treatment showed significant but manageable acute @entity2 . The long-term results seem encouraging and support further investigations in multimodal treatment of @entity4 .

title: Preoperative radiotherapy in combination with @entity5 for resectable XXXX : long-term results of a phase 2 study.

answer: @entity4


abstract: AIM: Surgery remains the main treatment of @entity3 . Poor long-term survival mandates the study of other techniques. An original treatment scheme with preoperative radiotherapy and @entity5 as a radiosensitizer is reported here. METHODS: Between 1982 and 1988, MRRC RAMS carried out a prospective clinical trial of preoperative radiotherapy (20 Gy/5 days) in combination with @entity5 (given orally, 3 times, 5 gms per metre(2)). Of 91 @entity0 who received preoperative radiotherapy, 67 @entity0 were operated on with curative intent and were eligible for further analysis. RESULTS: Acute gastro-intestinal @entity2 was significant but manageable without surgery delay in most cases. There were 4 postoperative deaths. Overall 5-year, 10-year survival and median survival were 46%, 36% and 46 months. Serosal and nodal involvement were the most significant adverse prognostic factors. Tumours confined to the gastric wall, node negative cases, middle and distal location, differentiated @entity1 , female sex and age more than 50 years were associated with relatively good long-term results: overall 5-year survival was 50% or better, overall 10-year survival was 40% or better. CONCLUSION: The combined treatment showed significant but manageable acute @entity2 . The long-term results seem encouraging and support further investigations in multimodal treatment of @entity4 .

title: Preoperative radiotherapy in combination with XXXX for resectable @entity4 : long-term results of a phase 2 study.

answer: @entity5


abstract: @entity5 , a @entity2 of @entity0 , is caused by the obligate intracellular bacterium @entity8 . Infection with @entity8 affects the peripheral nerves and the dermis, causing an accumulation of macrophages and other immune cells at the infected sites. Host resistance to the bacterium determines the extent of local inflammatory reactions and its resulting damage to the affected tissues. In @entity1 little if any cellular immunity develops. Bacterial multiplication is uncontrolled and @entity8 disseminate throughout most of the dermis. In @entity1 , marked cellular immunity is observed and bacterial growth and dissemination are controlled. The @entity3 of cellular immunity in @entity6 @entity0 is not fully understood. Since @entity8 cannot be grown in vitro, and a suitable animal model has not yet been developed, the study of host immunity to the pathogen is limited primarily to investigations of the cutaneous lesions of @entity0 and to in vitro responses of the peripheral blood leukocytes to @entity8 . While the blood monocytes of @entity5 @entity0 appear to be activated normally by lymphokines, T cell proliferation and production of lymphokines in response to @entity8 are impaired in @entity6 @entity0 . Attempts to restore responsiveness in cells from these @entity0 have been unsuccessful in our hands. The addition of exogenous @entity4 to leukocyte cultures does not appear to restore responsiveness to @entity8 in cells from nonresponsive @entity0 . Rather, some enhancement, often not antigen specific, is observed in cells from @entity0 with a preexisting response. Similarly, depletion of monocytes does not restore responsiveness to @entity8 in nonresponder @entity0 , but a nonspecific enhancement of proliferation is observed in monocyte-free cultures from @entity0 that do respond to @entity8 . Thus, the defect in @entity6 @entity0 does not result from a simple lack of @entity4 production or suppression by monocytes and/or their products. Possibly, there is a low level or lack of @entity8 -responsive T cells in the circulation of these @entity0 . Attempts to overcome the defect in immunity of @entity0 with @entity6 by immunoprophylaxis and immunotherapy are being investigated. This approach has become of major importance since the development of widespread drug resistance to @entity7 as well as to the other chemotherapeutic agents used to control @entity5 .

title: The immunobiology of XXXX .

answer: @entity5


abstract: The SufI protein and the @entity5 reductase (TorA) are the two best-characterized prototype proteins exported by the @entity1 TAT system. Whereas SufI does not contain cofactors, TorA is a molybdo-enzyme and the acquisition of the molybdo-cofactor is a prerequisite for its translocation. The overproduction of each protein leads to the saturation of its translocation, but it was unknown if the overproduction of one substrate could saturate the TAT apparatus and block thus the translocation of other TAT substrates. Here, we showed that the overproduction of SufI saturated only its own translocation, but had no effect of the translocation of TorA and other TAT substrate analyzed. To dissect the saturation mechanism of TorA translocation, we shortened by about one-third of the TorA protein and removed nine consensus molybdo-cofactor-binding ligands. Like SufI, the truncated TorA (TorA502) did not contain cofactor and would not compete with the full length TorA for molybdo-cofactor acquisition. The overproduction of TorA502 completely inhibited the export of the full length TorA and @entity3 ( @entity3 ) reductase, but had no effect on the translocation of SufI, @entity2 -induced @entity4 dehydrogenase and hydrogenase-2. Importantly, deletion of the twin- @entity0 signal peptide of TorA502 abolished the inhibitory effect. Moreover, the overproduction of the TorA signal peptide fused to the green fluorescence protein (GFP) was sufficient to block the TorA translocation. These results demonstrated that the twin- @entity0 signal peptide of the TorA protein specifically inhibits the translocation of a subset of TAT substrates, probably at the step of their targeting to the TAT apparatus.

title: Specific inhibition of the translocation of a subset of XXXX TAT substrates by the TorA signal peptide.

answer: @entity1


abstract: A well-controlled comparative study was conducted in order to evaluate the efficacy, safety and usefulness of the @entity7 antibiotic @entity5 ( @entity6 ) in complicated @entity1 ( @entity1 ) using @entity3 ( @entity4 ) as the control drug. @entity0 with complicated @entity1 due to Gram-negative bacteria were examined. However, in @entity2 , the cases caused by Gram-negative and Gram-positive bacteria were also examined. Both drugs were administered 1 g, twice a day by intravenous drip infusion for 5 days. Overall clinical efficacy was evaluated by the criteria proposed by the @entity1 committee in Japan. Of the total 394 cases, the clinical efficacy was evaluated for 152 cases in the @entity6 group and 143 cases in the @entity4 group excluding 99 cases of exclusion or dropout. There was no statistically significant difference in the back ground characteristics between the 2 groups. The overall clinical efficacy rate was 55.3% for @entity6 and 55.2% for @entity4 with difference not significant. As for clinical efficacy, in the monomicrobial infection after postprostatectomy ( @entity8 ), @entity6 was superior to @entity4 (P less than 0.05), whereas in the @entity2 without indwelling catheter ( @entity9 ), @entity4 was superior to @entity6 (P less than 0.1). The overall bacteriological eradication rate was 77.2% for @entity6 and 74.5% for @entity4 . For Gram-negative bacteria only the eradication rate for @entity6 (83.2%) was superior to that for @entity4 (74.6%). This was probably due to the stability of @entity6 to beta-lactamase. Side effects were observed in 3 cases out of 201 in the @entity6 group and 5 cases out of 189 in the @entity4 group. No severe abnormal laboratory finding was observed in any group; there was no significant difference between the 2 groups. Consequently, @entity6 was judged to be an antibiotic with clinical usefulness equal to, or even superior to that of @entity4 .

title: [Well-controlled comparative study on @entity5 and XXXX in the treatment of complicated @entity1 ].

answer: @entity3


abstract: A well-controlled comparative study was conducted in order to evaluate the efficacy, safety and usefulness of the @entity7 antibiotic @entity5 ( @entity6 ) in complicated @entity1 ( @entity1 ) using @entity3 ( @entity4 ) as the control drug. @entity0 with complicated @entity1 due to Gram-negative bacteria were examined. However, in @entity2 , the cases caused by Gram-negative and Gram-positive bacteria were also examined. Both drugs were administered 1 g, twice a day by intravenous drip infusion for 5 days. Overall clinical efficacy was evaluated by the criteria proposed by the @entity1 committee in Japan. Of the total 394 cases, the clinical efficacy was evaluated for 152 cases in the @entity6 group and 143 cases in the @entity4 group excluding 99 cases of exclusion or dropout. There was no statistically significant difference in the back ground characteristics between the 2 groups. The overall clinical efficacy rate was 55.3% for @entity6 and 55.2% for @entity4 with difference not significant. As for clinical efficacy, in the monomicrobial infection after postprostatectomy ( @entity8 ), @entity6 was superior to @entity4 (P less than 0.05), whereas in the @entity2 without indwelling catheter ( @entity9 ), @entity4 was superior to @entity6 (P less than 0.1). The overall bacteriological eradication rate was 77.2% for @entity6 and 74.5% for @entity4 . For Gram-negative bacteria only the eradication rate for @entity6 (83.2%) was superior to that for @entity4 (74.6%). This was probably due to the stability of @entity6 to beta-lactamase. Side effects were observed in 3 cases out of 201 in the @entity6 group and 5 cases out of 189 in the @entity4 group. No severe abnormal laboratory finding was observed in any group; there was no significant difference between the 2 groups. Consequently, @entity6 was judged to be an antibiotic with clinical usefulness equal to, or even superior to that of @entity4 .

title: [Well-controlled comparative study on @entity5 and @entity3 in the treatment of complicated XXXX ].

answer: @entity1


abstract: A well-controlled comparative study was conducted in order to evaluate the efficacy, safety and usefulness of the @entity7 antibiotic @entity5 ( @entity6 ) in complicated @entity1 ( @entity1 ) using @entity3 ( @entity4 ) as the control drug. @entity0 with complicated @entity1 due to Gram-negative bacteria were examined. However, in @entity2 , the cases caused by Gram-negative and Gram-positive bacteria were also examined. Both drugs were administered 1 g, twice a day by intravenous drip infusion for 5 days. Overall clinical efficacy was evaluated by the criteria proposed by the @entity1 committee in Japan. Of the total 394 cases, the clinical efficacy was evaluated for 152 cases in the @entity6 group and 143 cases in the @entity4 group excluding 99 cases of exclusion or dropout. There was no statistically significant difference in the back ground characteristics between the 2 groups. The overall clinical efficacy rate was 55.3% for @entity6 and 55.2% for @entity4 with difference not significant. As for clinical efficacy, in the monomicrobial infection after postprostatectomy ( @entity8 ), @entity6 was superior to @entity4 (P less than 0.05), whereas in the @entity2 without indwelling catheter ( @entity9 ), @entity4 was superior to @entity6 (P less than 0.1). The overall bacteriological eradication rate was 77.2% for @entity6 and 74.5% for @entity4 . For Gram-negative bacteria only the eradication rate for @entity6 (83.2%) was superior to that for @entity4 (74.6%). This was probably due to the stability of @entity6 to beta-lactamase. Side effects were observed in 3 cases out of 201 in the @entity6 group and 5 cases out of 189 in the @entity4 group. No severe abnormal laboratory finding was observed in any group; there was no significant difference between the 2 groups. Consequently, @entity6 was judged to be an antibiotic with clinical usefulness equal to, or even superior to that of @entity4 .

title: [Well-controlled comparative study on XXXX and @entity3 in the treatment of complicated @entity1 ].

answer: @entity5


abstract: The orofacial function in 20 @entity0 with Down syndrome was evaluated after 4 years of palatal plate therapy in 9 of the @entity0 ( @entity2 ); the remaining 11 were untreated age-matched controls (CG). All 20 @entity0 had received continuous orofacial physical therapy from their speech therapist during the treatment period. A clinical extra- and intraoral examination was performed, including oral motor function, facial expression, the occurrence of @entity3 , and @entity1 tonsils. A questionnaire requesting data on breathing patterns, drooling, eating problems, and communicative preferences was answered by the parents. An articulation assessment was performed by two speech and language pathologists blinded to the treatment status of the @entity0 in order to find out whether the palatal plate had stimulated to improved oral speech behavior. The results for oral motor function showed significant differences between the groups in favor of the @entity2 for the summary variables for: visible tongue (P < 0.01), visible tongue during non-speech periods (P < 0.05), and lip-rounding during spontaneous speech (P < 0.01). During non-speech time, the @entity2 had their mouths open significantly less than the CG (P < 0.05). Expressivity of facial expression on a visual analog scale in the @entity2 scored 75.6 +/- 13.3 compared to 51.8 +/- 25.7 in the CG (P < 0.05). The intraoral examination showed that 6/9 @entity0 in the @entity2 and 7/11 in the CG had enlarged tonsils, resulting in more than 50% inter-tonsillary space reduction. Despite these findings, and no significant differences between the groups with respect to mouth/ nose breathing, nocturnal snoring was significantly less in the @entity2 than in the CG (P < 0.05), according to the parental questionnaire. After 4 years of palatal plate therapy, orofacial function had improved significantly in the 9 @entity2 @entity0 and specifically in terms of tongue position and lip activity.

title: A four-year longitudinal study of palatal plate therapy in XXXX with Down syndrome: effects on oral motor function, articulation and communication preferences.

answer: @entity0


abstract: BACKGROUND: A prospective clinical trial was conducted to evaluate the conjunctive use of an extramedullary device and the bridge-plating technique in the treatment of @entity2 with major extension into the femoral shaft. METHODS: A Winquist criteria was used to classify 3 @entity3 patterns. The type 3 @entity3 were excluded from this study because of great extent of the @entity3 zone for which the bridge-plating technique is not indicated. There were 14 @entity0 and 6 @entity0 , with a mean age of 49 (range, 17-76) years. A dynamic hip screw (DHS) with a long side plate was chosen as the fixation device because of the small learning curve. RESULTS: The @entity3 united at a mean of 7.6 (range, 3-15) months postoperatively. Mobility was scored at 9 points in 18 @entity0 and 6 points in 2 @entity0 (Mobility score of Parker _ Palmer). @entity1 was absent in 14, mild in 3, and moderate in 3 @entity0 . Two limbs were shortened by 1 and 1.5 cm, respectively. CONCLUSION: Our results indicate that DHS fixation using the bridge-plating technique leads to union of all comminuted Winquist types 1 and 2 @entity3 without @entity4 , and it is a valuable alternative to new intramedullary devices. This procedure offers the significant advantage of being less technically demanding.

title: Bridge-plating osteosynthesis of 20 XXXX with dynamic hip screw.

answer: @entity2


abstract: A field trial has been carried out in Sudan to determine the optimum dosage regimen for the use of Oltipraz in the treatment of @entity2 in schoolchildren. A total of 294 @entity0 were treated in six groups to test 15 mg/kg, 20 mg/kg, and 25 mg/kg, using a single oral dose and a divided dose taken some 6 h apart. The @entity0 were interviewed before and then 24 h after treatment to determine the prevalence of drug-induced side-effects. Most of the @entity0 having complained of @entity3 before treatment, insisted that they suffered further @entity3 as a result of the drug. Four @entity0 complained of fingertip @entity1 . The latter side-effect had not previously been recorded in Sudan and, with the fingertip @entity1 , is a cause for concern. There was no difference in the cumulative failure rates between the single and the divided doses, but there was a significant improvement in the efficacy from the 15 mg/kg to the higher doses. The cumulative failure rate increased with higher pretreatment egg count. However at each level the reduction in egg count among failures at the 5-week follow-up, was significant at the 95% probability level. The efficacy of the drug was satisfactory when used at 20 or 25 mg/kg, but the strange side-effects need to be explained before any further use can be recommended.

title: Dose-finding trial using Oltipraz to treat schoolchildren infected with XXXX in Gezira, Sudan.

answer: @entity2


abstract: BACKGROUND: @entity4 from antimalarials is a well publicised cause of @entity5 and a great deal of time and resources are spent assessing it in relation to new drugs. The effect of the @entity2 parasite itself on hearing is, however, poorly documented and most evidence is anecdotal. This paper aims to collate existing evidence of this association. METHODS: Two systematic literature searches were performed on Ovid Medline, first for ' @entity2 ' and ' @entity3 ' or ' @entity3 ' or ' @entity5 ', and secondly for ' @entity1 '. The articles were then individually studied for relevance. RESULTS: @entity2 has been implicated as a rare cause of @entity3 in various studies, but recommendations and hypotheses have not been taken seriously or investigated. Searches also returned numerous studies of @entity1 after @entity6 , a small proportion of which observed hearing impairments on follow-up. However, no attempt was made to distinguish between treatment and disease as the cause. A few antimalarial drug trials which assessed hearing before treatment found unexplained @entity3 which improved with elimination of the parasite. CONCLUSION: Evidence from this review suggests that the @entity7 parasite is a potential cause of @entity3 . @entity2 is a disease of such high prevalence that even if only a small proportion of survivors develop this impairment the effects on @entity0 's education could be detrimental. More attention should be focussed on investigating this association as the clinical and pathophysiological implications are potentially considerable.

title: XXXX : @entity2 as a forgotten cause.

answer: @entity5


abstract: BACKGROUND: @entity4 from antimalarials is a well publicised cause of @entity5 and a great deal of time and resources are spent assessing it in relation to new drugs. The effect of the @entity2 parasite itself on hearing is, however, poorly documented and most evidence is anecdotal. This paper aims to collate existing evidence of this association. METHODS: Two systematic literature searches were performed on Ovid Medline, first for ' @entity2 ' and ' @entity3 ' or ' @entity3 ' or ' @entity5 ', and secondly for ' @entity1 '. The articles were then individually studied for relevance. RESULTS: @entity2 has been implicated as a rare cause of @entity3 in various studies, but recommendations and hypotheses have not been taken seriously or investigated. Searches also returned numerous studies of @entity1 after @entity6 , a small proportion of which observed hearing impairments on follow-up. However, no attempt was made to distinguish between treatment and disease as the cause. A few antimalarial drug trials which assessed hearing before treatment found unexplained @entity3 which improved with elimination of the parasite. CONCLUSION: Evidence from this review suggests that the @entity7 parasite is a potential cause of @entity3 . @entity2 is a disease of such high prevalence that even if only a small proportion of survivors develop this impairment the effects on @entity0 's education could be detrimental. More attention should be focussed on investigating this association as the clinical and pathophysiological implications are potentially considerable.

title: @entity5 : XXXX as a forgotten cause.

answer: @entity2


abstract: PURPOSE OF INVESTIGATION: To evaluate the pregnancy rate after laparoscopic treatment of @entity2 . @entity0 AND METHODS: 47 infertile @entity0 undergoing laparoscopic treatment of @entity2 . RESULTS: rAFS stage was as follows: 11% of @entity0 had Stage I, 11% Stage II, 53.3% Stage III and 24.4% Stage IV. The mean duration of follow-up was 48.5 +/- 18.44 months. The overall pregnancy rate was 64.4%. Eighteen out of 26 @entity0 (69%) became pregnant within six months after laparoscopy, 23% at 12 months, 11% within 24 months, and 11% after two years (p < 0.01). @entity3 and tubal status significantly affected the pregnancy rate. No differences were found regarding the stage of disease and the presence of @entity1 . CONCLUSION: Laparoscopic treatment of @entity2 enhances fertility and the pregnancy rate is highest within the first six months after surgery. @entity3 and tubal conditions influence the reproductive outcome.

title: Reproductive outcome after laparoscopic treatment of XXXX .

answer: @entity2


abstract: OBJECTIVES: The authors sought to understand the clinical and angiographic outcomes of dissections left after drug-coated balloon (DCB) angioplasty. BACKGROUND: Second-generation DCB may be an alternative to stents in selected populations for the treatment of native coronary lesions. However, the use of these devices may be hampered by a certain risk of acute vessel recoil or residual coronary dissection. Moreover, stenting after DCB has shown limited efficacy. Little is known about when a non-flow-limiting dissection is left after DCB angioplasty. METHODS: This was a prospective observational study whose aim was to investigate the outcome of a consecutive series of @entity0 with native @entity2 treated with second-generation DCB and residual coronary dissection at 2 Italian centers. We evaluated @entity0 clinical conditions at 1 and 9 months, and angiographic follow up was undertaken at 6 months. RESULTS: Between July 2012 and July 2014, 156 @entity0 were treated with DCB for native @entity2 . Fifty-two @entity0 had a final dissection, 4 of which underwent prosthesis implantation and 48 were left untreated and underwent angiographic follow-up after 201 days (interquartile range 161 to 250 days). The dissections were all type A to C, and none determined an impaired distal flow. Complete vessel healing at angiography was observed in 45 @entity0 (93.8%), whereas 3 @entity0 had persistent but uncomplicated dissections, and 3 had binary restenosis (6.2%). Late lumen loss was 0.14 mm (-0.14 to 0.42). Major adverse cardiovascular events occurred in 11 @entity0 in the entire cohort and in 4 of the dissection cohort (7.2% vs. 8.1%; p  = 0.48). We observed 8 and 3 @entity1 revascularizations, respectively (5.3% vs. 6.2%; p  = 0.37). CONCLUSIONS: In this cohort of consecutive @entity0 treated with new-generation DCB and left with a final dissection, this strategy of revascularization seemed associated with the sealing of most of dissections and without significant neointimal @entity3 .

title: Effect of Drug-Coated Balloons in  Native  XXXX Left  With a Dissection.

answer: @entity2


abstract: @entity7 ( @entity8 ) (3 g/day) and placebo were compared as an add-on to standard therapy in therapy-resistant @entity2 @entity0 using a double-blind crossover design with randomized treatment allocation. Twenty-three @entity0 entered the trial, with four dropping out due to either increased @entity4 frequency following the cross-over from GVG to placebo (n = 1), intolerance to GVG therapy (n = 2), or poor @entity4 record (n = 1). Of the 19 @entity0 who completed the study, 17 had partial @entity4 , eight of whom had secondary generalization and two who had primary generalized @entity4 . Compared with placebo, GVG was associated with a significant reduction in @entity4 frequency (p less than 0.01), with 11 of 19 @entity0 experiencing greater than 50% reduction in weekly @entity4 occurrence, two showing a 25-50% reduction, four unchanged, and two showing an increase in @entity4 . Global efficacy ratings were greater in the GVG period for 15 @entity0 (p less than 0.05) compared with one in whom there was no period difference and two in whom ratings were higher in the placebo period. Fourteen of the 19 @entity0 indicated a preference for the GVG period. Adverse effects observed during GVG treatment were generally mild and consisted of drowsiness, @entity5 , @entity3 , @entity1 , and @entity6 . No clinically significant alterations in laboratory test results were observed. No treatment-related changes in plasma concentrations of concomitant antiepileptic drugs were noted. These results confirm the antiepileptic efficacy of oral GVG in refractory @entity2 .

title: Double-blind, placebo-controlled study of @entity7 ( @entity7 ) in drug-resistant XXXX .

answer: @entity2


abstract: @entity7 ( @entity8 ) (3 g/day) and placebo were compared as an add-on to standard therapy in therapy-resistant @entity2 @entity0 using a double-blind crossover design with randomized treatment allocation. Twenty-three @entity0 entered the trial, with four dropping out due to either increased @entity4 frequency following the cross-over from GVG to placebo (n = 1), intolerance to GVG therapy (n = 2), or poor @entity4 record (n = 1). Of the 19 @entity0 who completed the study, 17 had partial @entity4 , eight of whom had secondary generalization and two who had primary generalized @entity4 . Compared with placebo, GVG was associated with a significant reduction in @entity4 frequency (p less than 0.01), with 11 of 19 @entity0 experiencing greater than 50% reduction in weekly @entity4 occurrence, two showing a 25-50% reduction, four unchanged, and two showing an increase in @entity4 . Global efficacy ratings were greater in the GVG period for 15 @entity0 (p less than 0.05) compared with one in whom there was no period difference and two in whom ratings were higher in the placebo period. Fourteen of the 19 @entity0 indicated a preference for the GVG period. Adverse effects observed during GVG treatment were generally mild and consisted of drowsiness, @entity5 , @entity3 , @entity1 , and @entity6 . No clinically significant alterations in laboratory test results were observed. No treatment-related changes in plasma concentrations of concomitant antiepileptic drugs were noted. These results confirm the antiepileptic efficacy of oral GVG in refractory @entity2 .

title: Double-blind, placebo-controlled study of XXXX ( @entity7 ) in drug-resistant @entity2 .

answer: @entity7


abstract: @entity7 ( @entity8 ) (3 g/day) and placebo were compared as an add-on to standard therapy in therapy-resistant @entity2 @entity0 using a double-blind crossover design with randomized treatment allocation. Twenty-three @entity0 entered the trial, with four dropping out due to either increased @entity4 frequency following the cross-over from GVG to placebo (n = 1), intolerance to GVG therapy (n = 2), or poor @entity4 record (n = 1). Of the 19 @entity0 who completed the study, 17 had partial @entity4 , eight of whom had secondary generalization and two who had primary generalized @entity4 . Compared with placebo, GVG was associated with a significant reduction in @entity4 frequency (p less than 0.01), with 11 of 19 @entity0 experiencing greater than 50% reduction in weekly @entity4 occurrence, two showing a 25-50% reduction, four unchanged, and two showing an increase in @entity4 . Global efficacy ratings were greater in the GVG period for 15 @entity0 (p less than 0.05) compared with one in whom there was no period difference and two in whom ratings were higher in the placebo period. Fourteen of the 19 @entity0 indicated a preference for the GVG period. Adverse effects observed during GVG treatment were generally mild and consisted of drowsiness, @entity5 , @entity3 , @entity1 , and @entity6 . No clinically significant alterations in laboratory test results were observed. No treatment-related changes in plasma concentrations of concomitant antiepileptic drugs were noted. These results confirm the antiepileptic efficacy of oral GVG in refractory @entity2 .

title: Double-blind, placebo-controlled study of @entity7 ( XXXX ) in drug-resistant @entity2 .

answer: @entity7


abstract: @entity3 are frequently found in soft tissue infections of the lower extremities in @entity1 @entity0 . The relative susceptibility to and persistence of soft tissue polymicrobial infections of @entity1 and nondiabetic @entity2 using bacteria commonly found in clinical foot infections were studied. Subcutaneous abscesses were induced in three groups of @entity1 and nondiabetic @entity2 using: (1) @entity4 and enterococcus, (2) enterococcus and @entity5 ( @entity5 ), and (3) @entity4 and @entity5 . Abscesses were removed at 1 and 2 wk for total colony counts. At 1 wk, there was a significantly greater bacterial growth in the abscesses of the @entity1 @entity2 compared with the nondiabetic @entity2 only in the group injected with enterococcus and @entity5 . There were significantly higher colony counts in the @entity1 compared with the nondiabetic @entity2 in all three groups at 2 wk after injection of the bacteria. Two weeks after injection of inocula containing @entity5 , both in combination with @entity4 or enterococcus, all nondiabetic @entity2 had eradicated @entity5 from the abscesses, but significant numbers of @entity5 persisted in the abscesses of the @entity1 @entity2 . In the @entity1 @entity2 , the presence of enterococci was more synergistic for growth of @entity5 than was the presence of @entity4 . These studies demonstrate that the bacteria of polymicrobial soft tissue infections persist for a longer period of time in the @entity1 compared with the nondiabetic host. In addition, @entity5 has increased pathogenicity in the @entity1 compared with the nondiabetic host, particularly in the presence of enterococci.

title: Persistence of polymicrobial abscesses in the poorly controlled XXXX host.

answer: @entity1


abstract: The mortality and morbidity were assessed during a 2-year follow-up in an acute intervention trial in suspected acute @entity2 with @entity5 (a selective beta 1-blocker). On admission to the trial, the 1395 participating @entity0 were randomly allocated to @entity5 or placebo for 3 months. Thereafter, if there was no contraindication, @entity0 with @entity4 and/or @entity3 were continued on @entity5 for 2 years. A lower mortality was observed after 3 months in @entity0 randomised to @entity5 . The difference remained after 2 years. The difference in 2-year mortality rate was restricted to @entity0 randomised early after onset of @entity1 . Late @entity4 was observed more often in the placebo group during the first 3 months. When the two groups thereafter were treated similarly, the difference successively declined and did not remain after 2 years. A similar incidence of @entity3 was observed in the two groups at each check up. During the early recovery period, more @entity0 in the @entity5 group returned to work. No such difference was observed later on.

title: The influence of early intervention in acute @entity2 on long-term mortality and morbidity as assessed in the G  teborg XXXX trial.

answer: @entity5


abstract: The mortality and morbidity were assessed during a 2-year follow-up in an acute intervention trial in suspected acute @entity2 with @entity5 (a selective beta 1-blocker). On admission to the trial, the 1395 participating @entity0 were randomly allocated to @entity5 or placebo for 3 months. Thereafter, if there was no contraindication, @entity0 with @entity4 and/or @entity3 were continued on @entity5 for 2 years. A lower mortality was observed after 3 months in @entity0 randomised to @entity5 . The difference remained after 2 years. The difference in 2-year mortality rate was restricted to @entity0 randomised early after onset of @entity1 . Late @entity4 was observed more often in the placebo group during the first 3 months. When the two groups thereafter were treated similarly, the difference successively declined and did not remain after 2 years. A similar incidence of @entity3 was observed in the two groups at each check up. During the early recovery period, more @entity0 in the @entity5 group returned to work. No such difference was observed later on.

title: The influence of early intervention in acute XXXX on long-term mortality and morbidity as assessed in the G  teborg @entity5 trial.

answer: @entity2


abstract: BACKGROUND: Successful transcatheter closure of @entity1 ( @entity1 ) requires the accurate assessment of defect size and morphology. Assessment of @entity2 anatomy may be difficult by two-dimensional (2D) echocardiography. The aim of this study was to test the hypothesis that real-time three-dimensional (3D) transesophageal echocardiography (TEE) may provide more accurate morphologic assessment of @entity1 than multiplane 2D TEE. METHODS: Twenty-four @entity0 with @entity1 were imaged using 2D and real-time 3D TEE. @entity2 shape and size were assessed using 3D TEE retrospectively. Maximal @entity2 dimensions obtained by 3D TEE were compared with unstretched and balloon-stretched dimensions on 2D TEE. Planimetered defect area by 3D TEE was compared with area calculated using the @entity3 formula from 2D imaging. Twenty of the 24 @entity0 underwent transcatheter @entity2 closure. Closure device size was based on findings on 2D TEE. Follow-up was conducted by 2D transthoracic echocardiography. RESULTS: Of the 24 @entity1 , 6 (25%) were circular, 10 (42%) were oval, and 8 (33%) were complex in shape. The mean maximal dimension was larger by 3D TEE compared with 2D TEE (1.8    0.8 vs 1.5    0.6 cm; P < .05). There was no difference in the mean area measured by either modality, but for complex-shaped defects, area measured by 3D TEE was larger than that by 2D TEE (2.8    1.3 vs 1.7    1.4 cm(2); P < .05). Follow-up transthoracic echocardiography was available for 19 of the 20 @entity0 undergoing transcatheter closure. Nine @entity0 had residual right-to-left shunting 1 to 6 months after @entity2 closure, and the majority of these were complex in shape. In @entity0 with residual shunting, @entity2 area by 3D TEE was 27% larger than by 2D TEE, whereas in @entity0 without residual shunting, there was significantly less discrepancy between 3D and 2D areas (19%; P  = .0027). CONCLUSIONS: Three-dimensional TEE can identify @entity2 shape. Maximal dimensions on 3D TEE were well correlated with balloon-stretched 2D dimensions. Two-dimensional TEE can underestimate the area of complex-shaped @entity1 , which may result in residual right-to-left shunting.

title: Real-time three-dimensional transesophageal echocardiography in @entity0 with secundum XXXX : outcomes following transcatheter closure.

answer: @entity1


abstract: BACKGROUND: Successful transcatheter closure of @entity1 ( @entity1 ) requires the accurate assessment of defect size and morphology. Assessment of @entity2 anatomy may be difficult by two-dimensional (2D) echocardiography. The aim of this study was to test the hypothesis that real-time three-dimensional (3D) transesophageal echocardiography (TEE) may provide more accurate morphologic assessment of @entity1 than multiplane 2D TEE. METHODS: Twenty-four @entity0 with @entity1 were imaged using 2D and real-time 3D TEE. @entity2 shape and size were assessed using 3D TEE retrospectively. Maximal @entity2 dimensions obtained by 3D TEE were compared with unstretched and balloon-stretched dimensions on 2D TEE. Planimetered defect area by 3D TEE was compared with area calculated using the @entity3 formula from 2D imaging. Twenty of the 24 @entity0 underwent transcatheter @entity2 closure. Closure device size was based on findings on 2D TEE. Follow-up was conducted by 2D transthoracic echocardiography. RESULTS: Of the 24 @entity1 , 6 (25%) were circular, 10 (42%) were oval, and 8 (33%) were complex in shape. The mean maximal dimension was larger by 3D TEE compared with 2D TEE (1.8    0.8 vs 1.5    0.6 cm; P < .05). There was no difference in the mean area measured by either modality, but for complex-shaped defects, area measured by 3D TEE was larger than that by 2D TEE (2.8    1.3 vs 1.7    1.4 cm(2); P < .05). Follow-up transthoracic echocardiography was available for 19 of the 20 @entity0 undergoing transcatheter closure. Nine @entity0 had residual right-to-left shunting 1 to 6 months after @entity2 closure, and the majority of these were complex in shape. In @entity0 with residual shunting, @entity2 area by 3D TEE was 27% larger than by 2D TEE, whereas in @entity0 without residual shunting, there was significantly less discrepancy between 3D and 2D areas (19%; P  = .0027). CONCLUSIONS: Three-dimensional TEE can identify @entity2 shape. Maximal dimensions on 3D TEE were well correlated with balloon-stretched 2D dimensions. Two-dimensional TEE can underestimate the area of complex-shaped @entity1 , which may result in residual right-to-left shunting.

title: Real-time three-dimensional transesophageal echocardiography in XXXX with secundum @entity1 : outcomes following transcatheter closure.

answer: @entity0


abstract: A multi-center study was carried out to compare the healing rates of @entity2 300 mg nocte and 150 mg b.i.d. in the short-term treatment of @entity1 and to assess the side-effect liability of @entity2 300 mg given in a single daily dose. Forty-five outpatients suffering from endoscopically and bioptically proven uncomplicated benign @entity1 were selected for the study. The @entity0 were treated, for 4 weeks, on the basis of a double-blind randomized design. An endoscopic examination was repeated within 4 days after the end of the treatments. The @entity0 who did not demonstrate complete healing were treated for an additional 4-week period. Clinical controls were performed to evaluate symptoms, antacid consumption, compliance with trial tablet consumption; hematological and biochemical tests were also carried out at the end of the 4 and 8-week periods. No differences were observed between the healing rate induced by 300 mg nocte and 150 mg b.i.d., after 4 weeks of treatment (76% and 79% respectively) and after 8 weeks (100% in both groups). Similar results were obtained as far as symptoms, antacid consumption and compliance are concerned. Neither treatment regimen induced appreciable side-effects.

title: A double-blind controlled trial of XXXX 300 mg nocte and @entity2 150 mg b.i.d. in the short-term treatment of @entity1 .

answer: @entity2


abstract: A multi-center study was carried out to compare the healing rates of @entity2 300 mg nocte and 150 mg b.i.d. in the short-term treatment of @entity1 and to assess the side-effect liability of @entity2 300 mg given in a single daily dose. Forty-five outpatients suffering from endoscopically and bioptically proven uncomplicated benign @entity1 were selected for the study. The @entity0 were treated, for 4 weeks, on the basis of a double-blind randomized design. An endoscopic examination was repeated within 4 days after the end of the treatments. The @entity0 who did not demonstrate complete healing were treated for an additional 4-week period. Clinical controls were performed to evaluate symptoms, antacid consumption, compliance with trial tablet consumption; hematological and biochemical tests were also carried out at the end of the 4 and 8-week periods. No differences were observed between the healing rate induced by 300 mg nocte and 150 mg b.i.d., after 4 weeks of treatment (76% and 79% respectively) and after 8 weeks (100% in both groups). Similar results were obtained as far as symptoms, antacid consumption and compliance are concerned. Neither treatment regimen induced appreciable side-effects.

title: A double-blind controlled trial of @entity2 300 mg nocte and XXXX 150 mg b.i.d. in the short-term treatment of @entity1 .

answer: @entity2


abstract: A multi-center study was carried out to compare the healing rates of @entity2 300 mg nocte and 150 mg b.i.d. in the short-term treatment of @entity1 and to assess the side-effect liability of @entity2 300 mg given in a single daily dose. Forty-five outpatients suffering from endoscopically and bioptically proven uncomplicated benign @entity1 were selected for the study. The @entity0 were treated, for 4 weeks, on the basis of a double-blind randomized design. An endoscopic examination was repeated within 4 days after the end of the treatments. The @entity0 who did not demonstrate complete healing were treated for an additional 4-week period. Clinical controls were performed to evaluate symptoms, antacid consumption, compliance with trial tablet consumption; hematological and biochemical tests were also carried out at the end of the 4 and 8-week periods. No differences were observed between the healing rate induced by 300 mg nocte and 150 mg b.i.d., after 4 weeks of treatment (76% and 79% respectively) and after 8 weeks (100% in both groups). Similar results were obtained as far as symptoms, antacid consumption and compliance are concerned. Neither treatment regimen induced appreciable side-effects.

title: A double-blind controlled trial of @entity2 300 mg nocte and @entity2 150 mg b.i.d. in the short-term treatment of XXXX .

answer: @entity1


abstract: A rational approach can be taken in the dental office to @entity1 and replantation. Consideration must be given to: Extraoral time. During this critical time, the prognosis for successful replantation noticeably decreases as the out-of-mouth time increases. Transport. Preferably the tooth will be transported in the socket, but milk or water may be used to keep the tooth moist. The buccal vestibule may be recommended for adults and teenagers but not for young @entity0 . Root surface. The root surface must not be handled, scraped, brushed, or have any part removed; it can be rinsed with sterile water, saline, or tap water but not with caustic solutions, disinfectants, or medicaments to clean the surface. Endodontic treatment. A tooth with an open apex should be evaluated bimonthly for revitalization. A tooth with a fully formed apex should have the pulp removed in 7 to 14 days after @entity1 . Status of the alveolar process. @entity2 may require a modified splint design to provide additional strength for a longer splinting duration. Obturation materials. @entity3 paste is used for a minimum of 6 to 24 months before filling permanently with gutta-percha. Selection of a splint. Each case is different and should be treated as such. Special consideration must be given to splint design, which will directly influence the desired result. Although any number of splints may be effective, inherent advantages and disadvantages of each should be understood fully by the clinician. This is where the art, the clinical experience, and the common sense of endodontic therapy dictate the proper splint and appropriate duration of splinting for the @entity0 .(ABSTRACT TRUNCATED AT 250 WORDS)

title: Splinting and replantation after traumatic XXXX .

answer: @entity1


abstract: Prostacyclin (PGI2) has been used extensively in @entity0 clinical trials and animal studies, but because of its instability, knowledge of its pharmacokinetics has progressed slowly. We assayed plasma PGI2 concentrations with a quantitative chromatographic method following bolus intravenous injection and during continuous infusion in @entity1 . Blood pressure response was correlated with plasma PGI2 concentrations and compared with the concentrations necessary to inhibit @entity4 in vitro. A two-compartment model was used to analyze the elimination kinetics for PGI2 after a single injection. The half-life of the terminal elimination phase was 2.7 minutes. The calculated systemic clearance and whole body volume of distribution were 93 ml/kg/min and 357 ml/kg, respectively. During continuous infusion, steady-state plasma concentrations were reached within 15 minutes and increased linearly with increasing infusion rate from 4.2 to 604 ng/kg/min, which resulted in PGI2 concentrations of 0.06 +/- 0.01 to 7.6 +/- 2.1 ng/ml, respectively. At steady-state plasma concentrations of PGI2 greater than 0.1 ng/ml, the mean arterial blood pressure decreased in a concentration-dependent manner, reaching a decrease of 45 mm Hg when the plasma concentration was 7.6 ng/ml. @entity5 caused a concentration-dependent inhibition of @entity3 -induced @entity4 in vitro with 10% inhibition at 0.4 ng/ml. These results indicate that in the @entity1 the level of PGI2 at which the onset of @entity2 occurs coincides with the inhibition of @entity4 .

title: Intravenous administration of @entity5 in XXXX : elimination kinetics and blood pressure response.

answer: @entity1


abstract: Prostacyclin (PGI2) has been used extensively in @entity0 clinical trials and animal studies, but because of its instability, knowledge of its pharmacokinetics has progressed slowly. We assayed plasma PGI2 concentrations with a quantitative chromatographic method following bolus intravenous injection and during continuous infusion in @entity1 . Blood pressure response was correlated with plasma PGI2 concentrations and compared with the concentrations necessary to inhibit @entity4 in vitro. A two-compartment model was used to analyze the elimination kinetics for PGI2 after a single injection. The half-life of the terminal elimination phase was 2.7 minutes. The calculated systemic clearance and whole body volume of distribution were 93 ml/kg/min and 357 ml/kg, respectively. During continuous infusion, steady-state plasma concentrations were reached within 15 minutes and increased linearly with increasing infusion rate from 4.2 to 604 ng/kg/min, which resulted in PGI2 concentrations of 0.06 +/- 0.01 to 7.6 +/- 2.1 ng/ml, respectively. At steady-state plasma concentrations of PGI2 greater than 0.1 ng/ml, the mean arterial blood pressure decreased in a concentration-dependent manner, reaching a decrease of 45 mm Hg when the plasma concentration was 7.6 ng/ml. @entity5 caused a concentration-dependent inhibition of @entity3 -induced @entity4 in vitro with 10% inhibition at 0.4 ng/ml. These results indicate that in the @entity1 the level of PGI2 at which the onset of @entity2 occurs coincides with the inhibition of @entity4 .

title: Intravenous administration of XXXX in @entity1 : elimination kinetics and blood pressure response.

answer: @entity5


abstract: A 55-year-old @entity0 was admitted to our hospital because of @entity16 , @entity15 , @entity6 , melena and leg @entity1 . Laboratory findings showed an increased serum @entity10 level (2.4 mg/dL), @entity9 and massive @entity8 (10.7 g/day). Renal biopsy revealed diffuse endocapillary proliferation and focal @entity17 with IgA deposition predominantly in the glomerular capillary walls. Based on these findings, he was diagnosed as having Henoch-Sch  nlein @entity18 and @entity2 therapy was started. Following @entity2 therapy, his @entity13 state remained unchanged, although his renal function improved concomitantly with the disappearance of @entity16 , @entity15 and abdominal symptoms. Therefore, @entity3 was added to the @entity2 therapy to enhance immunosuppression. However, melena recurred and @entity5 progressed. Endoscopy revealed @entity11 in the duodenum and jejunum, and clipping was performed at some @entity7 sites. However, he died of @entity7 . The autopsy revealed that @entity7 having @entity14 spread widely in the stomach, duodenum and jejunum. Recurrence of @entity4 during the treatment of Henoch-Sch  nlein @entity18 is usually due to severe @entity12 or @entity2 ulcer. However, in @entity0 receiving strong immunosuppressive therapy, @entity14 needs to be considered as cause of @entity4 .

title: [Autopsy case of Henoch-Sch  nlein XXXX complicated with intestinal @entity14 ].

answer: @entity18


abstract: A 55-year-old @entity0 was admitted to our hospital because of @entity16 , @entity15 , @entity6 , melena and leg @entity1 . Laboratory findings showed an increased serum @entity10 level (2.4 mg/dL), @entity9 and massive @entity8 (10.7 g/day). Renal biopsy revealed diffuse endocapillary proliferation and focal @entity17 with IgA deposition predominantly in the glomerular capillary walls. Based on these findings, he was diagnosed as having Henoch-Sch  nlein @entity18 and @entity2 therapy was started. Following @entity2 therapy, his @entity13 state remained unchanged, although his renal function improved concomitantly with the disappearance of @entity16 , @entity15 and abdominal symptoms. Therefore, @entity3 was added to the @entity2 therapy to enhance immunosuppression. However, melena recurred and @entity5 progressed. Endoscopy revealed @entity11 in the duodenum and jejunum, and clipping was performed at some @entity7 sites. However, he died of @entity7 . The autopsy revealed that @entity7 having @entity14 spread widely in the stomach, duodenum and jejunum. Recurrence of @entity4 during the treatment of Henoch-Sch  nlein @entity18 is usually due to severe @entity12 or @entity2 ulcer. However, in @entity0 receiving strong immunosuppressive therapy, @entity14 needs to be considered as cause of @entity4 .

title: [Autopsy case of Henoch-Sch  nlein @entity18 complicated with intestinal XXXX ].

answer: @entity14


abstract: Two types of modified distal splenorenal shunt with expanded @entity5 (Gore-Tex; WL Gore _ Associates Inc., Elkton, Md.) interposition were performed in 18 consecutive @entity0 with esophageal or esophagogastric varices. There were 12 @entity0 and six @entity0 ranging in age from 32 to 76 years. The causes of portal @entity2 were @entity6 in 15 @entity0 , chronic @entity1 in two, and @entity7 in one. In five @entity0 the left gastric vein branched off from the splenic vein; bilateral gastric venous decompression was achieved by preserving the splenic vein. Porta-azygos disconnection was routinely performed by confirming repeated intraoperative direct splenoportography. The operations were elective in seven and were @entity4 in five @entity0 . Six @entity0 underwent a prophylactic shunt; all @entity0 had "red color signs" endoscopically, and three of them had concomitant @entity3 . Postoperative morbidity was minimal and there was no mortality. Shunt patency was confirmed angiographically in all @entity0 14 to 56 days after surgery. The varices disappeared or significantly improved in all @entity0 . No @entity0 had variceal bleeding postoperatively. @entity1 was transiently seen in one (the oldest) @entity0 .

title: Modified distal splenorenal shunt with expanded XXXX interposition.

answer: @entity5


abstract: @entity2 -dependent binding of C-reactive protein (CRP) to @entity1 was determined by enzyme-linked immunosorbent assay. A homogenate of young hyphae was fractionated by hydrophobic interaction chromatography followed by gel filtration. High CRP-binding activity was found in a fraction of mol. wt c. 500,000 which was characterised by strong binding to the hydrophobic column. Three fractions of less conspicuous CRP-binding activity were identified (c. 500 000, 150 000 and 150 000-50 000 mol. wt respectively). In these four fractions, @entity3 was detected by an anti- @entity3 mouse hybridoma antibody. Some CRP-binding activity in fractions with low affinity for the hydrophobic column did not correspond closely with the presence of @entity3 . It is suggested that C-reactive substance in A. fumigatus is heterogeneous. The C-reactive substances did not correspond with fractions containing major antigens (470 000 and 250 000 mol. wt respectively) which elicit a strong immune response in @entity0 .

title: Binding of C-reactive protein to XXXX fractions.

answer: @entity1


abstract: BACKGROUND: Percutaneous absorption of topically applied 0.05% @entity4 ( @entity5 ) can be assessed indirectly by measuring @entity3 levels. A direct way is to measure systemic levels of topically applied @entity5 . METHODS: Serum concentrations of @entity5 were measured by liquid chromatography-tandem mass spectrometry (LC/ @entity1 / @entity1 ), and were related to serum @entity3 levels in 25 @entity0 with an exacerbation of @entity2 ( @entity2 ) before and after the first day of treatment with 0.05% @entity5 in hospital. The body surface area (BSA) affected by @entity2 was measured. RESULTS: Before the start of 0.05% @entity5 treatment, normal @entity3 levels were measured (0.47    0.18  mol/l) and @entity5 concentrations could not be detected. After the first day of treatment, @entity3 levels decreased to 0.04    0.05  mol/l. Serum concentrations of @entity5 could be detected in all @entity0 (0.112-4.504 ng/ml). Levels did not differ between @entity0 who had received two applications versus one application of 0.05% @entity5 . There was no correlation between the affected BSA and serum concentrations of @entity5 . CONCLUSION: Serum levels of @entity5 can be measured by LC/ @entity1 / @entity1 . When prescribing 0.05% @entity5 , one must bear in mind that, even after an application of 20-30 g, @entity5 is systemically available and potent enough to induce adrenal gland suppression.

title: The potency of @entity4 : serum levels of @entity4 and adrenal function during therapy with 0.05% @entity4 in @entity0 with severe XXXX .

answer: @entity2


abstract: BACKGROUND: Percutaneous absorption of topically applied 0.05% @entity4 ( @entity5 ) can be assessed indirectly by measuring @entity3 levels. A direct way is to measure systemic levels of topically applied @entity5 . METHODS: Serum concentrations of @entity5 were measured by liquid chromatography-tandem mass spectrometry (LC/ @entity1 / @entity1 ), and were related to serum @entity3 levels in 25 @entity0 with an exacerbation of @entity2 ( @entity2 ) before and after the first day of treatment with 0.05% @entity5 in hospital. The body surface area (BSA) affected by @entity2 was measured. RESULTS: Before the start of 0.05% @entity5 treatment, normal @entity3 levels were measured (0.47    0.18  mol/l) and @entity5 concentrations could not be detected. After the first day of treatment, @entity3 levels decreased to 0.04    0.05  mol/l. Serum concentrations of @entity5 could be detected in all @entity0 (0.112-4.504 ng/ml). Levels did not differ between @entity0 who had received two applications versus one application of 0.05% @entity5 . There was no correlation between the affected BSA and serum concentrations of @entity5 . CONCLUSION: Serum levels of @entity5 can be measured by LC/ @entity1 / @entity1 . When prescribing 0.05% @entity5 , one must bear in mind that, even after an application of 20-30 g, @entity5 is systemically available and potent enough to induce adrenal gland suppression.

title: The potency of XXXX : serum levels of @entity4 and adrenal function during therapy with 0.05% @entity4 in @entity0 with severe @entity2 .

answer: @entity4


abstract: BACKGROUND: Percutaneous absorption of topically applied 0.05% @entity4 ( @entity5 ) can be assessed indirectly by measuring @entity3 levels. A direct way is to measure systemic levels of topically applied @entity5 . METHODS: Serum concentrations of @entity5 were measured by liquid chromatography-tandem mass spectrometry (LC/ @entity1 / @entity1 ), and were related to serum @entity3 levels in 25 @entity0 with an exacerbation of @entity2 ( @entity2 ) before and after the first day of treatment with 0.05% @entity5 in hospital. The body surface area (BSA) affected by @entity2 was measured. RESULTS: Before the start of 0.05% @entity5 treatment, normal @entity3 levels were measured (0.47    0.18  mol/l) and @entity5 concentrations could not be detected. After the first day of treatment, @entity3 levels decreased to 0.04    0.05  mol/l. Serum concentrations of @entity5 could be detected in all @entity0 (0.112-4.504 ng/ml). Levels did not differ between @entity0 who had received two applications versus one application of 0.05% @entity5 . There was no correlation between the affected BSA and serum concentrations of @entity5 . CONCLUSION: Serum levels of @entity5 can be measured by LC/ @entity1 / @entity1 . When prescribing 0.05% @entity5 , one must bear in mind that, even after an application of 20-30 g, @entity5 is systemically available and potent enough to induce adrenal gland suppression.

title: The potency of @entity4 : serum levels of XXXX and adrenal function during therapy with 0.05% @entity4 in @entity0 with severe @entity2 .

answer: @entity4


abstract: BACKGROUND: Percutaneous absorption of topically applied 0.05% @entity4 ( @entity5 ) can be assessed indirectly by measuring @entity3 levels. A direct way is to measure systemic levels of topically applied @entity5 . METHODS: Serum concentrations of @entity5 were measured by liquid chromatography-tandem mass spectrometry (LC/ @entity1 / @entity1 ), and were related to serum @entity3 levels in 25 @entity0 with an exacerbation of @entity2 ( @entity2 ) before and after the first day of treatment with 0.05% @entity5 in hospital. The body surface area (BSA) affected by @entity2 was measured. RESULTS: Before the start of 0.05% @entity5 treatment, normal @entity3 levels were measured (0.47    0.18  mol/l) and @entity5 concentrations could not be detected. After the first day of treatment, @entity3 levels decreased to 0.04    0.05  mol/l. Serum concentrations of @entity5 could be detected in all @entity0 (0.112-4.504 ng/ml). Levels did not differ between @entity0 who had received two applications versus one application of 0.05% @entity5 . There was no correlation between the affected BSA and serum concentrations of @entity5 . CONCLUSION: Serum levels of @entity5 can be measured by LC/ @entity1 / @entity1 . When prescribing 0.05% @entity5 , one must bear in mind that, even after an application of 20-30 g, @entity5 is systemically available and potent enough to induce adrenal gland suppression.

title: The potency of @entity4 : serum levels of @entity4 and adrenal function during therapy with 0.05% XXXX in @entity0 with severe @entity2 .

answer: @entity4


abstract: BACKGROUND: Percutaneous absorption of topically applied 0.05% @entity4 ( @entity5 ) can be assessed indirectly by measuring @entity3 levels. A direct way is to measure systemic levels of topically applied @entity5 . METHODS: Serum concentrations of @entity5 were measured by liquid chromatography-tandem mass spectrometry (LC/ @entity1 / @entity1 ), and were related to serum @entity3 levels in 25 @entity0 with an exacerbation of @entity2 ( @entity2 ) before and after the first day of treatment with 0.05% @entity5 in hospital. The body surface area (BSA) affected by @entity2 was measured. RESULTS: Before the start of 0.05% @entity5 treatment, normal @entity3 levels were measured (0.47    0.18  mol/l) and @entity5 concentrations could not be detected. After the first day of treatment, @entity3 levels decreased to 0.04    0.05  mol/l. Serum concentrations of @entity5 could be detected in all @entity0 (0.112-4.504 ng/ml). Levels did not differ between @entity0 who had received two applications versus one application of 0.05% @entity5 . There was no correlation between the affected BSA and serum concentrations of @entity5 . CONCLUSION: Serum levels of @entity5 can be measured by LC/ @entity1 / @entity1 . When prescribing 0.05% @entity5 , one must bear in mind that, even after an application of 20-30 g, @entity5 is systemically available and potent enough to induce adrenal gland suppression.

title: The potency of @entity4 : serum levels of @entity4 and adrenal function during therapy with 0.05% @entity4 in XXXX with severe @entity2 .

answer: @entity0


abstract: BACKGROUND: The aim was to evaluate the effect of a single intravitreal ranibizumab injection in eyes with non-arteritic anterior @entity2 . METHODS: Four eyes of four @entity0 comprised the study group. In addition to a standard ocular examination, visual field testing and retinal nerve fibre layer thickness analysis were performed prior to injection and one and three months after the injection. RESULTS: Mean time between @entity1 and the intravitreal injection was 7.8 days (range, 2-15 days). The mean age of @entity0 was 58.2 years (range, 45-63 years). After a single dose of ranibizumab injection, all @entity0 experienced a @entity1 . Mean visual acuity (VA) was 1.15    0.26 logMar before the injection and improved to 0.37    0.09 logMar at the third post-injection month. The mean retinal nerve fibre layer thickness measured with spectral domain optical coherence tomography significantly decreased after the injection in all eyes. No complication related to the injections was observed during the following three months. CONCLUSION: Intravitreal ranibizumab injection may be a treatment option in eyes with non-arteritic anterior @entity2 and a short disease history.

title: Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior XXXX .

answer: @entity2


abstract: @entity4 ( @entity4 ) is generally considered to be a benign periampullary lesion, although it is unclear whether it should be classified as a @entity5 or as a @entity2 . Here, we present a @entity4 case with lymph node @entity1 . A 16-year-old @entity0 complained of exertional @entity3 . Upper endoscopy and imaging studies revealed a polypoid @entity2 . Pancreaticoduodenectomy with lymph node dissection was performed due to swelling of peripancreatic lymph nodes. Histologically, the @entity2 consisted of three cell types: epithelioid; spindle; and ganglion cells. In addition to these typical components of @entity4 , a distinct glandular component was also present. There was substantial invasion of @entity2 cells into the lymphovascular vessels, associated with lymph node @entity1 . These lymph node @entity1 were histologically similar to the @entity2 . To judge from these findings @entity4 may be a true @entity2 with metastatic capacity. Pre- and intraoperative investigations for lymph node or distant @entity1 are required for adequate resection of this kind of @entity2 .

title: @entity4 with regional lymph node XXXX and a glandular component.

answer: @entity1


abstract: @entity4 ( @entity4 ) is generally considered to be a benign periampullary lesion, although it is unclear whether it should be classified as a @entity5 or as a @entity2 . Here, we present a @entity4 case with lymph node @entity1 . A 16-year-old @entity0 complained of exertional @entity3 . Upper endoscopy and imaging studies revealed a polypoid @entity2 . Pancreaticoduodenectomy with lymph node dissection was performed due to swelling of peripancreatic lymph nodes. Histologically, the @entity2 consisted of three cell types: epithelioid; spindle; and ganglion cells. In addition to these typical components of @entity4 , a distinct glandular component was also present. There was substantial invasion of @entity2 cells into the lymphovascular vessels, associated with lymph node @entity1 . These lymph node @entity1 were histologically similar to the @entity2 . To judge from these findings @entity4 may be a true @entity2 with metastatic capacity. Pre- and intraoperative investigations for lymph node or distant @entity1 are required for adequate resection of this kind of @entity2 .

title: XXXX with regional lymph node @entity1 and a glandular component.

answer: @entity4


abstract: OBJECTIVES: Most gastrointestinal (GI) illness within the UK goes undetected by routine surveillance. A national telephone helpline for health advice (NHS Direct) offers a new source of data on @entity2 . We aim to describe NHS Direct calls suggestive of @entity2 and the outcome of these calls. METHODS: Details of over 150000 telephone calls were collected from NHS Direct over a 6-month period. Calls about ' @entity1 ', ' @entity3 ' or ' @entity4 ' were defined as GI calls and described according to the age of the @entity0 and call outcome. RESULTS: Gastrointestinal calls accounted for 10.3% of total calls (' @entity1 '=4.9%, ' @entity3 '=5.1%). GI calls as a proportion of total calls were significantly high in @entity0 under 1 year (23.5%) and aged 1-4 years (21.5%). Call outcomes which resulted in further NHS care being recommended accounted for 72.3% of total calls and 54.5% of GI calls. CONCLUSIONS: A high proportion of NHS Direct calls were about GI symptoms especially for @entity0 under 5 years. When compared with all NHS Direct calls, GI calls were less likely to result in further NHS care being recommended. Analysis of NHS Direct calls provides further insight into @entity2 in the community.

title: What can analysis of calls to NHS direct tell us about the epidemiology of XXXX in the community?

answer: @entity2


abstract: To evaluate the prognostic value of LP-PLA2 and hs-CRP to the stability of @entity3 . Forty-eight New Zealand White @entity0 were randomly divided into control group, stable plaque group, P53 group, and P53 + drug group. @entity0 in the control group were fed a regular diet. @entity0 in stable plaque group, P53 group, and P53 + drug group underwent balloon-induced @entity4 and then were fed a diet of 1% @entity2 . Then the @entity0 in the P53 group and P53 + drug group underwent Ad5- @entity5 P53 transfection in the 10th week; The P53 + drug group underwent pharmacologic triggering with @entity6 venom (RVV) and @entity1 in 24 h and 48 h before euthanized. Intravascular ultrasound (IVUS) was used before sacrificing of the animal. In the 0 week and 12th week, @entity0 underwent fast blood collection from the medium-sized artery of the ears, and the serum LP-PLA2 and hs-CRP level was determined. The animal altherosclerotic (AS) model was successfully gained and the rules of serum LP-PLA2 and hs-CRP level in instable plaque were discovered: serum LP-PLA2 in P53 group and P53 + drug group were significantly different from the control group and the stable group, while hs-CRP failed to differ between the control group and the stable group and succeeded in different degrees of unstable plague. The relationship analysis of serum and IVUS results revealed LP-PLA2 might predict an instability of plaque. Combining serum Lp-PLA2 and hs-CRP has higher specificity in predicting the vulnerability of the plaque.

title: Prognostic value of serum LP-PLA2 and hs-CRP in unstable XXXX .

answer: @entity3


abstract: This study analyzes the value of surgery in the treatment, staging and long-term survival of 17 @entity0 affected with primary @entity3 . In 7 @entity0 the @entity1 was localized to the lower third of the stomach, in three to the middle third, in two to the upper third, while in 5 @entity0 there was involvement of the entire stomach. @entity0 were classified according to the Ann-Arbor classification. Nine @entity0 were stage Ie, five stage Ile, and three stage IVe. A partial gastrectomy was carried out in ten @entity0 and total gastrectomy in 7. In all cases surgical excision of the @entity3 was performed together with intraoperative staging including bilateral hepatic biopsies, and exploration of all abdominal lymph nodes. Two @entity2 occurred among the 7 @entity0 who underwent total gastrectomy but no major complications were observed in the remaining 5 @entity0 . No @entity2 occurred among the 10 @entity0 who underwent partial gastrectomy, but in one case an acute complication developed. Staging laparotomy permitted the correction of clinical staging, and showed that three cases were understaged and one overstaged. All @entity0 received adjuvant chemio-radiotherapy. All but one @entity0 are currently alive, well and free of disease. Survival was correlated significantly with the stage of the disease and extent of gastric involvement, but there was no correlation between survival, histological grade, and the type of gastrectomy performed.

title: Surgery in primary XXXX : impact on clinical staging and long-term survival.

answer: @entity3


abstract: Glycolysis is one of the central routes of @entity0 catabolism in @entity3 . Several glycolytic enzymes, including the key enzyme @entity4 dehydrogenase, are encoded in the hexacistronic gapA operon. Expression of this operon is induced by a variety of @entity2 and @entity1 . Under non-inducing conditions, expression is repressed by the CggR repressor protein, the product of the promoter-proximal gene of the operon. Here, it is shown that the amount of @entity4 dehydrogenase encoded by the second gene of the operon exceeds that of the CggR repressor by about 100-fold. This differential synthesis was attributed to an mRNA processing event that takes place at the 3' end of the cggR open reading frame and to differential segmental stabilities of the resulting cleavage products. The mRNA specifying the truncated cggR gene is quickly degraded, whereas the downstream processing products encompassing gapA are quite stable. This increased stability is conferred by the presence of a stem-loop structure at the 5' end of the processed mRNAs. Mutations were introduced in the region of the cleavage site. A mutation affecting the stability of the stem-loop structure immediately downstream of the processing site had two effects. First, the steady-state transcript pattern was drastically shifted towards the primary transcripts; second, the stability of the processed mRNA containing the destabilized stem-loop structure was strongly decreased. This results in a reduction of the amount of @entity4 dehydrogenase in the cell. It is concluded that mRNA processing is involved in differential syntheses of the proteins encoded by the gapA operon.

title: Expression of the glycolytic gapA operon in XXXX : differential syntheses of proteins encoded by the operon.

answer: @entity3


abstract: OBJECTIVE: To investigate the reproductive performance of non-pregnant @entity0 with @entity7 ( @entity7 ) and the association between @entity7 and @entity6 ( @entity6 ) in reproductive failure. SUBJECTS AND METHODS: Fifty non-pregnant @entity0 with 3 or more consecutive @entity7 attending our @entity7 clinic were evaluated prospectively. Detailed history and physical examination were completed. Extensive laboratory investigations, ultrasonographic, radiological and specialized procedures/tests were performed. Those @entity0 who did not achieve pregnancy within the first 6 months of follow-up had appropriate treatment options implemented. The outcome of any subsequent pregnancies was analyzed. RESULTS: The mean age of the @entity0 was 33.8 +/- 4.6 years (range 22-43 years). The aetiological factors associated with @entity7 were @entity4 , @entity2 , @entity3 , @entity6 and @entity1 ; 40% were 'unexplained'. Thirty @entity0 (60%) were able to achieve viable pregnancies which progressed to term, resulting in live births. Fourteen of the other 20 @entity0 had high body mass index (BMI) >30 and evidence of @entity6 . Of these 20 @entity0 , 13 eventually achieved pregnancies which ended again in first-second-trimester abortions (cause undetermined). The remaining 7 @entity0 (4 with high BMI) who had a combination of male factor/protracted @entity6 / @entity5 did not achieve pregnancies. CONCLUSION: The association of @entity7 with @entity6 resulted in poor reproductive performance, which may progress to reproductive failure.

title: The relationship of XXXX with reproductive failure.

answer: @entity7


abstract: BACKGROUND: @entity3 causes severe @entity2 that can seriously compromise respiratory mechanics and exacerbate underlying @entity5 and pre-existing @entity8 , predisposing to @entity8 . The cornerstone of management is early institution of effective @entity2 relief, the subject of this review. METHODS: A MEDLINE search was conducted for the years 1966 through and up to December 2002 for @entity0 studies written in English using the keywords " @entity3 ", " @entity7 ", "blunt @entity6 ", " @entity6 ". The reference list of key articles was also searched for relevant articles. The various analgesic techniques used in @entity0 with multiple @entity3 were summarized. RESULTS: Analgesia could be provided using systemic opioids, transcutaneous electrical nerve stimulation or non steroidal anti-inflammatory drugs. Alternatively, regional analgesic techniques such as @entity4 , epidural @entity7 , intrathecal opioids, interpleural @entity7 and thoracic @entity4 have been used effectively. Although invasive, in general, regional blocks tend to be more effective than systemic opioids, and produce less systemic side effects. CONCLUSION: Based on current evidence it is difficult to recommend a single method that can be safely and effectively used for @entity7 in all circumstances in @entity0 with multiple @entity3 . By understanding the strengths and weaknesses of each analgesic technique, the clinician can weigh the risks and benefits and individualize @entity2 management based on the clinical setting and the extent of @entity1 .

title: Acute @entity2 management of @entity0 with multiple XXXX .

answer: @entity3


abstract: BACKGROUND: @entity3 causes severe @entity2 that can seriously compromise respiratory mechanics and exacerbate underlying @entity5 and pre-existing @entity8 , predisposing to @entity8 . The cornerstone of management is early institution of effective @entity2 relief, the subject of this review. METHODS: A MEDLINE search was conducted for the years 1966 through and up to December 2002 for @entity0 studies written in English using the keywords " @entity3 ", " @entity7 ", "blunt @entity6 ", " @entity6 ". The reference list of key articles was also searched for relevant articles. The various analgesic techniques used in @entity0 with multiple @entity3 were summarized. RESULTS: Analgesia could be provided using systemic opioids, transcutaneous electrical nerve stimulation or non steroidal anti-inflammatory drugs. Alternatively, regional analgesic techniques such as @entity4 , epidural @entity7 , intrathecal opioids, interpleural @entity7 and thoracic @entity4 have been used effectively. Although invasive, in general, regional blocks tend to be more effective than systemic opioids, and produce less systemic side effects. CONCLUSION: Based on current evidence it is difficult to recommend a single method that can be safely and effectively used for @entity7 in all circumstances in @entity0 with multiple @entity3 . By understanding the strengths and weaknesses of each analgesic technique, the clinician can weigh the risks and benefits and individualize @entity2 management based on the clinical setting and the extent of @entity1 .

title: Acute XXXX management of @entity0 with multiple @entity3 .

answer: @entity2


abstract: BACKGROUND: @entity3 causes severe @entity2 that can seriously compromise respiratory mechanics and exacerbate underlying @entity5 and pre-existing @entity8 , predisposing to @entity8 . The cornerstone of management is early institution of effective @entity2 relief, the subject of this review. METHODS: A MEDLINE search was conducted for the years 1966 through and up to December 2002 for @entity0 studies written in English using the keywords " @entity3 ", " @entity7 ", "blunt @entity6 ", " @entity6 ". The reference list of key articles was also searched for relevant articles. The various analgesic techniques used in @entity0 with multiple @entity3 were summarized. RESULTS: Analgesia could be provided using systemic opioids, transcutaneous electrical nerve stimulation or non steroidal anti-inflammatory drugs. Alternatively, regional analgesic techniques such as @entity4 , epidural @entity7 , intrathecal opioids, interpleural @entity7 and thoracic @entity4 have been used effectively. Although invasive, in general, regional blocks tend to be more effective than systemic opioids, and produce less systemic side effects. CONCLUSION: Based on current evidence it is difficult to recommend a single method that can be safely and effectively used for @entity7 in all circumstances in @entity0 with multiple @entity3 . By understanding the strengths and weaknesses of each analgesic technique, the clinician can weigh the risks and benefits and individualize @entity2 management based on the clinical setting and the extent of @entity1 .

title: Acute @entity2 management of XXXX with multiple @entity3 .

answer: @entity0